ArticleCancers2023
Efficacy of Thermal Ablation for Small-Size (0-3 cm) versus Intermediate-Size (3-5 cm) Colorectal Liver Metastases: Results from the Amsterdam Colorectal Liver Met Registry (AmCORE).
Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 21 citations in OpenAlex.
- Microwave ablation versus stereotactic body radiotherapy for oligometastatic colorectal liver metastases (LAVA-CRLM): a prospective, randomised, phase II trial.The Lancet regional health. Europe · 2026Article
- [Interventional therapeutic strategies for metastatic liver cancer].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Review
- Thermal Ablation for Colorectal Liver Metastases: Current Evidence and Future Horizons.Diagnostics (Basel, Switzerland) · 2026Review
- Article
- Safety and Efficacy of High Power (> 100W) Microwave Ablation Using the EMPRINT™ HP System: Final Results of a Post-Market Clinical Follow-Up Study.Cardiovascular and interventional radiology · 2026Article
- Impact of Tumor Size on Outcomes of Hepatic Arteriography and C-Arm CT-Guided Ablation (HepACAGA): > 3 cm Is No Absolute Contraindication.Cardiovascular and interventional radiology · 2026Article
- Repeat ablation and single-session ablation in patients with multiple colorectal cancer liver metastases after chemotherapy failure.World journal of gastroenterology · 2025Article
- Prognostic analysis of patients with CRLM based on CRS score: a single-center retrospective study.BMC cancer · 2025Article
- Prognostic Comparison of Complete vs. Incomplete Radiofrequency Ablation for Colorectal Liver Metastases: A Multicenter Prospective Study.Cancer medicine · 2025Article
- Oncologic Outcomes after Percutaneous Ablation for Colorectal Liver Metastases: An Updated Comprehensive Review.Medicina (Kaunas, Lithuania) · 2024Review
- Article
- Configuring thermal ablation volumes for treatment of distinct tumor shapes: a repeatability study using a robotic approach.Frontiers in oncology · 2024Article
- Optimizing Treatment Strategy for Oligometastases/Oligo-Recurrence of Colorectal Cancer.Cancers · 2023Review
- Review
- High-Level Standardization of Ablative Procedures: The Way to Go.Cardiovascular and interventional radiology · 2023Article
- Echo-guided Local Ablation for Liver Metastasis (Taiwan Academy of Tumor Ablation Guideline).Journal of medical ultrasoundArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThermal ablation is widely recognized as the standard of care for small-size unresectable colorectal liver metastases (CRLM). For larger CRLM safety, local control and overall efficacy are not well established and insufficiently validated. The purpose of this comparative series was to analyze outcomes for intermediate-size versus small-size CRLM. MATERIAL AND
methodsPatients treated with thermal ablation between December 2000 and November 2021 for small-size and intermediate-size CRLM were included. The primary endpoints were complication rate and local control (LC). Secondary endpoints included local tumor progression-free survival (LTPFS) and overall survival (OS).
resultsIn total, 59 patients were included in the intermediate-size (3-5 cm) group and 221 in the small-size (0-3 cm) group. Complications were not significantly different between the two groups (
conclusionsThermal ablation for intermediate-size unresectable CRLM is safe and induces long-term LC in the vast majority. The results of the COLLISION-XL trial (unresectable colorectal liver metastases: stereotactic body radiotherapy versus microwave ablation-a phase II randomized controlled trial for CRLM 3-5 cm) are required to provide further clarification of the role of local ablative methods for intermediate-size unresectable CRLM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.